AUTHORS
Qian Chen, MD, Hao Yao, MD2, Jialiang Lu, PhD3, Haiyan Yang, PhD4
AFFILIATIONS
1 Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany, Heidelberg, Germany, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
2 Department of Haematology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität-Erlangen-Nürnberg (FAU), Germany, Erlangen, Germany
3 College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
4 Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
ABSTRACT
Background
Acute myeloid leukemia (AML) remains a clinical challenge due to disease relapse and chemoresistance, driven largely by the self-renewal of leukemia stem cells (LSCs) and a blocked differentiation program[1,2]. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in hematopoietic malignancies[3,4]. However, the therapeutic potential and precise mechanisms of specific functional lncRNAs within the LSC compartment remain to be fully characterized[5]. In this study, we identified LINC00889 as a novel, highly enriched lncRNA in the LSC compartment and aims to elucidate the functional role, upstream and downstream regulation mechanism in AML stemness and leukemogenesis.
Methods
LINC00899 expression was analyzed in sorted AML LSCs, non-LSCs, normal hematopoietic stem/progenitor cells (HSPCs), and public AML cohorts including TCGA and Leucegene. H3K27ac, MENIN, MLL, and Pol II ChIP-seq were used to assess chromatin and transcriptional regulation at the LINC00899 locus. LINC00899 function was examined using shRNA-mediated knockdown, lentiviral-based overexpression, colony-forming unit assays, flow cytometry, and limiting dilution transplantation experiments. Primary AML patient samples were used to establish PDX mouse models to evaluate the functional impact of LINC00899 in vivo. RNA-seq were utilized to evaluate transcriptomic alterations following LINC00899 knockdown (shLINC).
Results
LINC00889 was found to be highly enriched in AML LSC populations (LSCs) compared with non-LSCs and normal HSPCs. In the public AML cohorts from Leucegene dataset, higher LINC00899 expression was associated with LSC-high AML patients and inferior overall survival. H3K27ac ChIP-seq showed increased active chromatin signals at the LINC00899 locus in LSCs compared with HSPCs, supporting LSC-associated epigenetic activation.
Functionally, LINC00899 knockdown markedly reduced colony formation in primary AML samples. In the PDX model, LINC00899 knockdown decreased leukemic burden and delayed AML progression. Conversely, LINC00899 overexpression in primary AML patient-derived cells enhanced bone marrow engraftment in mice in vivo. In limiting dilution transplantation assays, LINC00899 overexpression increased the estimated leukemia stem cell frequency from 1 in 20,120 to 1 in 4,789 (p=0.0302).
Mechanistically, LINC00899 expression correlated strongly with HOXA/HOXB cluster genes and MEIS1 in the TCGA AML cohort. MENIN and MLL ChIP-seq revealed binding enrichment at the LINC00899 locus in AML cells, while the menin inhibitor VTP-50469 reduced Pol II recruitment and LINC00899 transcription, identifying LINC00899 as a downstream target of the MENIN–MLL leukemic transcriptional axis.
RNA-seq following LINC00899 knockdown demonstrated significant suppression of E2F target genes and G2/M checkpoint pathways. Additionally, flow cytometric analysis revealed increased G1-phase accumulation and reduced S/G2/M-phase populations. Moreover, LINC00899 knockdown induced differentiation-associated phenotypic changes in AML cells. Among candidate downstream effectors, CCND3 emerged as a key mediator as it's expression was reduced following LINC00899 knockdown at both transcriptional and chromatin-associated levels. CCND3 overexpression largely rescued the impaired colony-forming capacity induced by LINC00899 depletion.
Conclusion
Our study identifies LINC00899 as a critical regulator of AML stemness and leukemogenesis. LINC00899 is epigenetically activated by the MENIN–MLL transcriptional axis and sustains LSC function through CCND3-mediated cell-cycle regulation. These findings reveal a previously unrecognized lncRNA-dependent mechanism underlying AML maintenance and highlight the LINC00899–CCND3 axis as a potential therapeutic vulnerability for targeting leukemia stem cells.
References
[1] Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 2017, 129(12):1577-1585.
[2] Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. New Engl J Med 2015, 373(12):1136-1152.
[3] Rinn JL, Chang HY. Long noncoding RNAs: molecular modalities to organismal functions. Annu Rev Biochem 2020, 89:283-308.
[4] Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111(6):3183-3189.
[5] Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011, 1(5):391-407.
DISCLOSURES
Qian Chen, MD: No relevant conflicts of interest to declare.